` KNSA (Kiniksa Pharmaceuticals Ltd) vs S&P 500 Comparison - Alpha Spread

KNSA
vs
S&P 500

Over the past 12 months, KNSA has underperformed S&P 500, delivering a return of +10% compared to the S&P 500's +16% growth.

Stocks Performance
KNSA vs S&P 500

Loading
KNSA
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
KNSA vs S&P 500

Loading
KNSA
S&P 500
Difference
www.alphaspread.com

Performance By Year
KNSA vs S&P 500

Loading
KNSA
S&P 500
Add Stock

Competitors Performance
Kiniksa Pharmaceuticals Ltd vs Peers

S&P 500
KNSA
ABBV
CYTH
AMGN
GILD
Add Stock

Kiniksa Pharmaceuticals Ltd
Glance View

Market Cap
2B USD
Industry
Biotechnology

Founded with a vision to tackle some of the most challenging inflammatory and autoimmune diseases, Kiniksa Pharmaceuticals Ltd. emerged as a nimble player in the competitive biotechnology landscape. This company, leveraging the vast potential of advanced scientific knowledge and biotechnological breakthroughs, focuses on developing and commercializing innovative therapies. Its portfolio is strategically designed to address unmet needs in the treatment of debilitating diseases. Central to its operations is a robust pipeline of monoclonal antibodies and cutting-edge biologics that promise new hope for patients. Guided by a commitment to rigorous clinical development and strategic collaborations, Kiniksa seeks to navigate the complexities of regulatory pathways, bringing its specialized therapeutic solutions to global markets. The financial engine of Kiniksa's ambitious journey is fueled by a combination of strategic partnerships, successful licensing agreements, and prudent capital allocation. By forging alliances with larger pharmaceutical firms, the company gains access to invaluable resources and distribution channels while minimizing its financial risks. This collaborative approach not only expedites the development process but also amplifies market reach, ensuring that novel treatments are accessible to the patients who need them. Revenue streams are bolstered through a mix of upfront payments, milestone achievements, and royalties as its therapies progress through stages of clinical trials and, finally, into the hands of healthcare providers. This business model, one that intertwines innovation with strategic alliances, is designed to sustain growth, balance risk, and ultimately fulfill the company's mission of transforming patients’ lives.

KNSA Intrinsic Value
37.36 USD
Undervaluation 26%
Intrinsic Value
Price
Back to Top